Beyond Your Cancer

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Patients Treated

Isoray Medical, Inc. is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.

Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.

Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.

The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.

In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.

The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.

In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.

Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.

Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.


Review our SEC Filings, Codes of Conduct, & Management Teams.


We are always looking for talented people to join our team.

IsoRay Announces First Quarter Fiscal 2018 Financial Results

Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., Nov. 14, 2017 (GLOBE NEWSWIRE) --...

Even when faced with aggressive prostate cancer, know ALL of your treatment options

It bears repeating: in recent conversations with multiple prostate cancer survivors and the physicians that treat them, we hear again and again how...

(No) Incontinence After Brachytherapy

One side effect of many prostate cancer treatment options is possible incontinence. Removing the prostate through surgery or weakening it during...

Can prostate cancer treatment really be “easy?” Brachytherapy experience in survivors’ own words.

“I was surprised by how easy it was.” - Carl Janssens, Prostate Cancer Survivor on Brachytherapy. “[After the treatment] we walked out and went...

Once a cancer survivor, now a pioneer in brachytherapy and radiation oncology

In 1997 Dr. Brian Moran helped found the Chicago Prostate Cancer Center. A graduate of the Loyola Stritch School of Medicine, he is board-certified...

Join Us at the Following Events


American Society for Therapeutic Radiation Oncology

September 24 – 27, 2017 San Diego Convention Center San Diego, CA


Society of Thoracic Surgery

2018 Annual Meeting January 27-31, 2018 Fort Lauderdale, FL


American Association of Neurological Surgeons

April 30 - May 2, 2018 New Orleans, LA


American Urologic Association Annual Meeting 2018

May 18-22, 2018 San Francisco, CA


American Brachytherapy Society

2018 ABS Annual Meeting June 7-9, 2018 San Francisco, CA

Recent News

IsoRay Announces First Quarter Fiscal 2018 Financial Results

Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., Nov. 14, 2017 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...

Prostate cancer survivor Dave Ricordati: “Do your own homework.” During Dave’s initial diagnosis for prostate cancer, his primary care physician and his urologist did not steer him toward brachytherapy. “Assuming you are not going to...

WKYT: “Lexington cancer doctor saving women’s lives”

Cesium-131 Brachytherapy pioneer, Dr. Jonathan Feddock was recently featured by WKYT, leading the fight against recurrent gynecologic cancer. “It's estimated every six minutes in this country, a doctor diagnoses a woman with gynecologic cancer or cancer of the...

New guidelines and targeted treatment: insights from AUA 2017

Amidst a trove of news surrounding prostate cancer treatment, the 2017 edition of the American Urological Association annual conference convened earlier this month in Boston. The meeting hosted approximately 10,000 attendees and maintained its focus on prostate cancer...